MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS; ENDOVASCULAR SYSTEM FOR TREATMENT OF THORACOABDOMINAL AND PARARENAL AORTIC LESIO

Catalog Number	ATAA43120160A
Medical Device Problem Code	Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code	Coagulation Disorder (1779)
Date of Event	02/28/2025
Type of Reportable Event	Death
Event or Problem Description
The following information was reported: on (b)(6) 2025, the patient underwent treatment of an aortic aneurysm using a gore® excluder® thoracoabdominal branch endoprosthesis (tambe).It was reported that the right renal artery was cannulated and stented, then the left renal artery, then the superior mesenteric artery (sma) and last the celiac artery.The procedure for the tambe took approximately three hours.Upon the final completion angiogram, it was noted that the renal arteries did not have flow.The physician cannulated the renal arteries and discovered both renal arteries had thrombus present.The physician preformed a thrombectomy with penumbra where she reestablished flow.Intravascular ultrasound (ivus) was used to visualize the renal arteries to make sure the stents where not crushed.Everything looked appropriate via ivus.During this time, the physician discovered that anesthesia had been struggling keeping the activated clotting time (act) therapeutic.With act¿s being below 200.The patient was switched over to argatroban, at that point the patient¿s act went to therapeutic levels.The patient¿s labs were sent in to determine if the patient had heparin-induced thrombocytopenia (hitt), that came back negative.As the sheath was coming out of the groin, the physician noticed no pulses in the accessed leg.Upon further investigation it was determined the left leg had thrombosed as well.The physician preformed a cut down on the access and did a thrombectomy where flow was reestablished.On march 04, 2025, the field sales associate was called by the physician and informed that the patient was experiencing abdominal pain and had a lactic acid of over 6, patient received a cta and discovered all 4 visceral vessels where thrombosed.The physician took the patient back to the operating room where a thrombectomy was performed of the celiac artery and sma.Flow was established however branch vessels had thrombus still present.The patient ultimately went into renal and liver failure and passed away on (b)(6)2025.
Additional Manufacturer Narrative
Patient medications: albuterol hfa, norvasc, eliquis, aspirin, acetaminophen, albumin human 5% infusion, cathflo activase, argatroban, artificial tears ophthalmic solution, pulmicort, calcium chloride, coreg, mefoxin, decadron, folic-acid, fentanyl, apresoline, dilaudid, omnipaque, and trandate.The gore® excluder® thoracoabdominal branch endoprosthesis (tambe) instructions for use (ifu) states that adverse events that may occur and/or require intervention include but are not limited to arterial or venous thrombosis and occlusion of device or native vessel.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
Additional Manufacturer Narrative
Correction section d.
Additional Manufacturer Narrative
Correction to h1, further determination, this will be deemed a reportable death.

• Brand Name: GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
• Common Device Name: ENDOVASCULAR SYSTEM FOR TREATMENT OF THORACOABDOMINAL AND PARARENAL AORTIC LESIO
• Manufacturer (Section D): W. L. GORE & ASSOCIATES, INC.; 1505 n. fourth street; flagstaff AZ 86004
• Manufacturer (Section G): MEDICAL WOODY SPRINGS B/P; 3450 w. kiltie lane; flagstaff AZ 86005
• Manufacturer Contact: rachael chascsa ; 1505 n. fourth street; flagstaff, AZ 86004 ; 9285263030
• MDR Report Key: 21684245
• Report Number: 2017233-2025-05968
• Device Sequence Number: 9308649
• Product Code: QZK
• UDI-Device Identifier: 00733132659678
• UDI-Public: (01)00733132659678(17)271015
• Combination Product (Y/N): N
• Initial Reporter State: NC
• Initial Reporter Country: US
• PMA/510(K) Number: P230023
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Device Implanted Year: 2025
• Serviced by Third Party (Y/N): N
• Reporter Type: Manufacturer
• Report Source: Company Representative
• Initial Reporter Occupation: Physician
• Type of Report: Initial,Followup,Followup
• Report Date (Section B): 04/16/2025

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Operator of Device: Health Professional
• Device Catalogue Number: ATAA43120160A
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 03/04/2025
• Supplement Date Received by Manufacturer: Not provided; Not provided
• Initial Report FDA Received Date: 03/24/2025
• Supplement Report FDA Received Date: 04/08/2025; 04/17/2025
• Was Device Evaluated by Manufacturer? (Y/N): Device Not Returned to Manufacturer
• Date Device Manufactured: 10/16/2024
• Is the Device Labeled for Single Use? (Y/N): Yes
• Usage of Device: Initial
• Patient Sequence Number: 1
• Outcome Attributed to Adverse Event: Hospitalization; Required Intervention
• Patient Age: 55 YR
• Patient Sex: Female